<SEC-DOCUMENT>0001193125-21-036661.txt : 20210211
<SEC-HEADER>0001193125-21-036661.hdr.sgml : 20210211
<ACCEPTANCE-DATETIME>20210210193359
ACCESSION NUMBER:		0001193125-21-036661
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210210
FILED AS OF DATE:		20210211
DATE AS OF CHANGE:		20210210

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ImmunoPrecise Antibodies Ltd.
		CENTRAL INDEX KEY:			0001715925
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39530
		FILM NUMBER:		21615913

	BUSINESS ADDRESS:	
		STREET 1:		880 - 580 HORNBY STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C3B6
		BUSINESS PHONE:		6048060626

	MAIL ADDRESS:	
		STREET 1:		880 - 580 HORNBY STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C3B6
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d124368d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of February 2021 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">001-39530</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ImmunoPrecise Antibodies Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>3204 - 4464
Markham Street, Victoria, British Columbia V8Z 7X8 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&#9746;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d124368dex991.htm">News Release dated February&nbsp;10, 2021 </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>IMMUNOPRECISE ANTIBODIES LTD.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: February&nbsp;10, 2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Lisa Helbling</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Lisa Helbling</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d124368dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g124368g0211030312926.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IPA Announces Closing of Over-Allotment Option Associated with the Recently Completed Bought Deal Offering of Common
Shares </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VICTORIA, British Columbia, February&nbsp;10, 2021<B> </B>&#150; IMMUNOPRECISE ANTIBODIES LTD. (the &#147;Company&#148; or &#147;IPA&#148;)
(NASDAQ: IPA / TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that the over-allotment option (the &#147;Option&#148;) granted in connection with its previously announced bought deal
offering of 1,616,293 common shares (the &#147;Common Shares&#148;) in the capital of the Company (the &#147;Offering&#148;), has been fully exercised. H.C. Wainwright&nbsp;&amp; Co. has purchased additional 242,443 shares of the Company (the
&#147;Additional Shares&#148;) at the public offering price of $13.45 per Additional Share for additional aggregate gross proceeds to the Company of approximately $3.3&nbsp;million, less underwriting discounts and commissions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">H. C. Wainwright &amp; Co., acted as sole book-running manager for the Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company intends to use the net proceeds from the Offering and the issuance and sale of the Additional Shares for (i)&nbsp;pursuing the Company&#146;s
objective of expanding its operations into Good Laboratory Practice and Good Manufacturing Practice-certified; (ii)&nbsp;the development and commercialization of Talem Therapeutics, LLC&#146;s, a wholly owned subsidiary of the Company, internal and
partnered therapeutic discovery programs; (iii)&nbsp;investments in employees, partnerships, cloud computing, data curation and analysis to enable further work toward the development of custom algorithms, cloud computing, large-scale sequence data
analysis, and expanded access to next-generation sequencing technologies; (iv)&nbsp;the development of its PolyTope<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> approach to the development of innovative therapeutics and vaccines against
the <FONT STYLE="white-space:nowrap">COVID-19;</FONT> and (v)&nbsp;general corporate and working capital purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Offering, the
Company filed with the securities regulatory authorities in each of the provinces of Canada (except Quebec), a short form base shelf prospectus dated December&nbsp;11, 2020. The short form base shelf prospectus was filed on Form <FONT
STYLE="white-space:nowrap">F-10</FONT> with the U.S. Securities and Exchange Commission (&#147;SEC&#148;). The Company also filed a preliminary prospectus supplement to the short form base shelf prospectus with the securities regulatory authority in
the Province of British Columbia as well as with the SEC as part of a registration statement on Form <FONT STYLE="white-space:nowrap">F-10</FONT> under the U.S.-Canada multijurisdictional disclosure system (&#147;MJDS&#148;). The Common Shares were
only offered and sold in the United States either directly or through duly registered U.S. broker dealers. No Common Shares were offered or sold to Canadian purchasers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Offering was made in the United States only by means of the registration statement, including the base shelf prospectus and applicable prospectus
supplement. Such documents contain important information about the Offering. A short form base shelf prospectus and accompanying preliminary prospectus supplement have been filed with the SEC and are available for free on the SEC&#146;s website at
www.sec.gov and on the SEDAR website at www.sedar.com. Copies of the short form base shelf prospectus and accompanying final prospectus supplement have been filed with the SEC and are available for free on the SEC&#146;s website at www.sec.gov and
on the SEDAR website at www.sedar.com. Electronic copies of the final prospectus supplement and registration statement may also be obtained from H.C. Wainwright&nbsp;&amp; Co., LLC, 430 Park Avenue 3rd Floor, New York, NY 10022, or by calling (646) <FONT
STYLE="white-space:nowrap">975-6996</FONT> or by emailing placements@hcwco.com. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No securities regulatory authority has either approved or disapproved the contents of this news release.
This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of any such province, state or jurisdiction.<B> </B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About ImmunoPrecise Antibodies
Ltd. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IPA is a global technology platform company with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT>
solutions empowering companies to discover and develop therapies against any disease. The Company&#146;s experience and cutting-edge technologies enable unparalleled support of its partners in their quest to bring innovative treatments to the
clinic. IPA&#146;s full-service capabilities dramatically reduce the time required for, and the inherent risk associated with, conventional multi-vendor product development. For further information, visit www.immunoprecise.com or contact
solutions@immunoprecise.com.<B> </B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This news release contains forward-looking statements and forward-looking information within the meaning of applicable United States securities laws and
Canadian securities laws (together, the &#147;forward-looking statements&#148;. Forward-looking statements are often identified by the use of words such as &#147;plans&#148;, &#147;expects&#148; or &#147;does not expect&#148;, &#147;is
expected&#148;, &#147;estimates&#148;, &#147;intends&#148;, &#147;anticipates&#148; or &#147;does not anticipate&#148;, or &#147;believes&#148;, or variations of such words and phrases or state that certain actions, events or results
&#147;may&#148;, &#147;could&#148;, &#147;would&#148;, &#147;might&#148; or &#147;will&#148; be taken, occur or be achieved. Forward-looking statements contained in this news release include, but are not limited to, statements relating to the
Offering, including the use of proceeds from the Offering. In respect of the forward-looking statements contained herein, the Company has provided such statements and information in reliance on certain assumptions that management believed to be
reasonable at the time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results,
performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The Offering is subject to numerous factors, many of which are beyond
the Company&#146;s control, including but not limited to, market and other conditions and other important factors disclosed previously and from time to time in the Company&#146;s filings with the securities regulatory authorities in each of the
provinces of Canada and the SEC. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from
those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking statements contained in this news release. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date.
The Company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SOURCE ImmunoPrecise Antibodies Ltd. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fr&eacute;d&eacute;ric Chabot, Phone:
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-438-863-7071,</FONT></FONT></FONT> Email: frederick@contactfinancial.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g124368g0211030312926.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g124368g0211030312926.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !F FX# 2(  A$! Q$!_\0
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M^E^'K%KS5;V*UA' +GECZ =2?I2::=AW6YI45Y;+\>?"J3[([;4Y(P?]8(5
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M^']Y/-&IFMB)(G(Y4Y[5\O=J(2YT$H\K/LJ._35/"GV^/[MQ:&0?BM?'$_\
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MD58L6,33W]O$HR7D4#\Z]:\5+L\*7B_W8L5R'@/0I+B]&J3(1!%_J\C[S?\
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MNKFU=5VRIMP<#W-?1%%"J-2Y@<$U8^?OA5X+\2Z+XZM[S4M&N;6V6)P9)-N
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
..444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
